• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

Reports quantify rising U.S. meds tab, adding fresh fuel for debate

May 4, 2017
By Michael Fitzhugh
In the bitter political battle over a potential replacement for the Affordable Care Act, common ground between rivals can seem scarce. Yet, right there in the middle is one of the top priorities across parties: lowering the cost of prescription drugs.
Read More

U.S. trade rep names the usual suspects; PhRMA adds Australia

May 3, 2017
By Michael Fitzhugh
Ongoing market access barriers for U.S. pharma and medical device companies landed India, Canada and Colombia on the U.S. Trade Representative's annual "Special 301" watch list again. The USTR's annual report reviews global developments on trade and intellectual property, identifying trading partners that USTR, part of the Executive Office of the President, deems to have harmful records on protection, enforcement or market access for U.S. innovators and creators.
Read More

U.S. Trade Representative names and shames the usual suspects

May 2, 2017
By Michael Fitzhugh

U.S. trade rep names the usual suspects; PhRMA adds Australia

May 2, 2017
By Michael Fitzhugh
Ongoing market access barriers for U.S. pharma and medical device companies landed India, Canada and Colombia on the U.S. Trade Representative’s annual “Special 301” watch list again.
Read More

Ariad wins accelerated approval for second-line NSCLC drug brigatinib

May 2, 2017
By Michael Fitzhugh
Takeda Pharmaceutical Co. Ltd. subsidiary Ariad Pharmaceuticals Inc. won accelerated approval from the FDA for Alunbrig (brigatinib). The approval covers the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) who have progressed on or are intolerant to Pfizer Inc.’s Xalkori (crizotinib).
Read More

Rydapt ratified: Novartis' targeted AML therapy wins FDA approval

May 1, 2017
By Michael Fitzhugh
FDA approval has arrived for Novartis AG's Rydapt (midostaurin), a breakthrough-designated treatment for adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). The oral, multitargeted kinase inhibitor, approved for use in combination with chemotherapy and a companion diagnostic developed by Invivoscribe Technologies Inc. to detect the FLT3 mutation, is the first targeted therapy to treat patients with AML.
Read More

Following positive CHMP review, Biomarin scores FDA approval for Batten disease therapy

April 28, 2017
By Michael Fitzhugh

Biomarin Pharmaceutical Inc. has won FDA approval for Brineura (cerliponase alfa), the first therapy for children with the rare and fatal neurodegenerative condition ceroid lipofuscinosis type 2 (CLN2). The enzyme replacement therapy was approved to slow the loss of walking ability in symptomatic children, 3 years and older, with the late infantile form of the condition.


Read More

Arsanis to carry pneumonia prevention MAb through phase II with $45.5M series D

April 27, 2017
By Michael Fitzhugh
Arsanis Inc., an infectious disease specialist developing a targeted monoclonal antibody to prevent Staphylococcus aureus pneumonia, has closed on a $45.5 million series D financing that will help it complete a phase II trial of candidate ASN-100 in high-risk mechanically ventilated patients. The new funds will also support the advancement of preclinical gram-negative programs, as well as a respiratory syncytial virus (RSV) program.
Read More

EASL updates its hepatitis B guidelines to include Vemlidy

April 26, 2017
By Michael Fitzhugh
AMSTERDAM – Hepatitis B treatment guidelines, newly updated by the European Association for the Study of the Liver to help doctors navigate what EASL governing board member Frank Tacke told BioWorld Today is "lots of dynamic change" during the last couple years, have become the first to recommend the use of the most recently approved HBV drug, Vemlidy.
Read More

Capricor trial yields positive data in DMD-linked heart disease

April 26, 2017
By Michael Fitzhugh
Patients with Duchenne muscular dystrophy (DMD) and advanced heart disease enrolled in an exploratory study of Capricor Therapeutics Inc.'s candidate, CAP-1002, saw, at the study's six-month midpoint, improved measures of cardiac structure and upper limb function. The interim data suggest that the therapy, composed of allogeneic cardiosphere-derived cells, could help stave off decompensated heart failure, a common cause of death for individuals with DMD.
Read More
Previous 1 2 … 110 111 112 113 114 115 116 117 118 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe